TNFSF10 and prostate cancer: A single chain antibody scFv62, derived from mAb62, was fused to the tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and was shown to induce apoptosis and to sensitise prostate cancer cells to chemotherapeutics in vitro (Hartung et al. 2011; Hartung and Pardo 2016).